EIGR - セラドン (Eiger BioPharmaceuticals Inc.) セラドン

 EIGRのチャート


 EIGRの企業情報

symbol EIGR
会社名 Eiger BioPharmaceuticals Inc (セラドン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Eiger BioPharmaceuticals Inc. formerly Celladon Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV) exendin (9-39) for severe hypoglycemia and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara Turkey) LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.   セラドンは心臓血管疾患の遺伝子治療の開発に焦点を置く米国のバイオ医薬品会社。筋小胞体カルシウムATPア―ゼ(SERCA2:細胞内のカルシウムを制御する酵素)をタ―ゲットした心不全の治療薬「MYDICAR」の治験を行う。また、糖尿病や神経変性疾患に対するSERCA2の開発を行う。   
本社所在地 2155 Park Boulevard Palo Alto CA 94306 USA
代表者氏名 David A Cory デビッド・ア・コーリー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-279-9845
設立年月日 36861
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 16人
url www.celladon.com
nasdaq_url https://www.nasdaq.com/symbol/eigr
adr_tso
EBITDA EBITDA(百万ドル) -37.52800
終値(lastsale) 11.2
時価総額(marketcap) 159535846.4
時価総額 時価総額(百万ドル) 158.39630
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 105.17830
当期純利益 当期純利益(百万ドル) -38.80900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eiger Biopharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $18.7M. Lower net loss reflects Research and development - Balancing val decrease of 27% to $11.1M (expense) Stock-based Compensation in SGA decrease of 14% to $1.5M (expense) Interest Income increase of 27% to $283K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.68 to -$1.66.

 EIGRのテクニカル分析


 EIGRのニュース

   Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism  2021/02/23 13:00:00 PR Newswire
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that positive…
   Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021  2021/02/08 13:00:00 PR Newswire
PALO ALTO, Calif., Feb. 8, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that final…
   Experimental drug can speed up COVID-19 recovery: Study  2021/02/08 09:32:51 The Tribune
Toronto, February 8 Scientists have found that an experimental antiviral drug can significantly speed up recovery in COVID-19 patients who do not need hospitalisation, an advance that may lead to better interventions to treat those infected with the novel coronavirus. The study, published in the journal Lancet Respiratory Medicine, noted that patients who received a single injection of the drug peginterferon-lambda were over four times more likely to have cleared the infection within seven days compared to a group treated with placebo. "This treatment has large therapeutic potential, especially at this moment as we see aggressive variants of the virus spreading around the globe which are less sensitive to both vaccines and treatment with antibodie," said study co-author Jordan Feld from the Toronto Centre for Liver Disease in Canada. According to the researchers, people who were treated with the drug cleared the virus quickly with the effect being most pronounced in those with the highest viral levels. "We also saw a trend towards quicker improvement of respiratory symptoms in the treatment group," Feld explained.
   Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies  2021/01/25 13:00:00 PR Newswire
PALO ALTO, Calif., Jan. 25, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial…
   Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates  2020/11/28 18:08:21 Benzinga
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions. Supernus Pharmaceuticals Inc (NASDAQ: SUPN ), Alkermes Plc (NASDAQ: ALKS ), Adamis Pharmaceuticals Corp (NASDAQ: ADMP ), Bristol-Myers Squibb Co (NYSE: BMY ), Liquidia Technologies Inc (NASDAQ: LQDA ) and Revance Therapeutics Inc (NASDAQ: RVNC ) were among the companies that either received complete response letters (which indicate that the application is not ready for approval) or saw the review periods extended. Notable among the approvals issued during the month were Eiger Biopharmaceuticals Inc 's (NASDAQ: EIGR ) progeria treatment Zokinvy and Sanofi SA's (NASDAQ: SNY ) sutimlimab for treating hemolysis in adult patients with cold agglutinin disease. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) was fortunate to get the FDA nod for its Oxlumo drug to treat primary hyperoxaluria type 1, ahead of the Dec. 3 PDUFA date.
   Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies  2021/01/25 13:00:00 PR Newswire
PALO ALTO, Calif., Jan. 25, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial…
   Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates  2020/11/28 18:08:21 Benzinga
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions. Supernus Pharmaceuticals Inc (NASDAQ: SUPN ), Alkermes Plc (NASDAQ: ALKS ), Adamis Pharmaceuticals Corp (NASDAQ: ADMP ), Bristol-Myers Squibb Co (NYSE: BMY ), Liquidia Technologies Inc (NASDAQ: LQDA ) and Revance Therapeutics Inc (NASDAQ: RVNC ) were among the companies that either received complete response letters (which indicate that the application is not ready for approval) or saw the review periods extended. Notable among the approvals issued during the month were Eiger Biopharmaceuticals Inc 's (NASDAQ: EIGR ) progeria treatment Zokinvy and Sanofi SA's (NASDAQ: SNY ) sutimlimab for treating hemolysis in adult patients with cold agglutinin disease. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) was fortunate to get the FDA nod for its Oxlumo drug to treat primary hyperoxaluria type 1, ahead of the Dec. 3 PDUFA date.
   FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know  2020/11/23 15:45:58 Benzinga
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR )'s … Full story available on Benzinga.com
   Proceeds from Priority Review Voucher Sale Will Fund Search for Cure for the Rapid Aging Disease Progeria  2020/11/23 13:01:00 PR Newswire
PEABODY, Mass., Nov. 23, 2020 /PRNewswire/ -- The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV). Earlier today, Eiger BioPharmaceuticals, Inc. (Eiger) announced that it has entered into a…
   Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies  2020/11/20 22:53:00 PR Newswire
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved…
   Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies  2021/01/25 13:00:00 PR Newswire
PALO ALTO, Calif., Jan. 25, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial…
   Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates  2020/11/28 18:08:21 Benzinga
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions. Supernus Pharmaceuticals Inc (NASDAQ: SUPN ), Alkermes Plc (NASDAQ: ALKS ), Adamis Pharmaceuticals Corp (NASDAQ: ADMP ), Bristol-Myers Squibb Co (NYSE: BMY ), Liquidia Technologies Inc (NASDAQ: LQDA ) and Revance Therapeutics Inc (NASDAQ: RVNC ) were among the companies that either received complete response letters (which indicate that the application is not ready for approval) or saw the review periods extended. Notable among the approvals issued during the month were Eiger Biopharmaceuticals Inc 's (NASDAQ: EIGR ) progeria treatment Zokinvy and Sanofi SA's (NASDAQ: SNY ) sutimlimab for treating hemolysis in adult patients with cold agglutinin disease. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) was fortunate to get the FDA nod for its Oxlumo drug to treat primary hyperoxaluria type 1, ahead of the Dec. 3 PDUFA date.
   FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know  2020/11/23 15:45:58 Benzinga
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR )'s … Full story available on Benzinga.com
   Proceeds from Priority Review Voucher Sale Will Fund Search for Cure for the Rapid Aging Disease Progeria  2020/11/23 13:01:00 PR Newswire
PEABODY, Mass., Nov. 23, 2020 /PRNewswire/ -- The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV). Earlier today, Eiger BioPharmaceuticals, Inc. (Eiger) announced that it has entered into a…
   Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies  2020/11/20 22:53:00 PR Newswire
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セラドン EIGR Eiger BioPharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)